It presents as brown to red-purplish nodules, papules and plaques on the extensor surface of the extremities. It may present with features of leukocytoclastic vasculitis at the early stage, while at later stage it shows fibrosis and granulation tissue. Dapsone is currently the most effective treatment. Other therapies include surgical excision, methotrexate, colchicine, antibiotics and steroids. This paper will present a review
Introduction
Erythema elevatum diutinum (EED) is a rare chronic leukocytoclastic vasculitis dermatosis of unknown aetiology that was described by Hutchinson in 1888 and in 1894 was named by Radcliffe-Crocker and Williams .It presents as brown to red-purplish nodules, papules and plaques on the extensor surface of the extremities [1] . It tends to present earlier in patients diagnosed with HIV and most commonly presents between the 4th to 6th decade although it can present at any age and has no racial predilection [2] . The most common associated symptom is arthralgia [2] . Skin biopsy is important to make a diagnosis of (EED).Dapsone is currently the most effective treatment [2] . Other therapies include surgical excision, methotrexate, colchicine, antibiotics and steroids.
Treatment
In a review of 66 cases of EED treated with dapsone monotherapy lead to complete resolution in 80 % of the cases of EED. Treatment with steroids was initiated but there was no improvement, later on dapsone therapy at high doses failed to bring any improvement so therapy was discontinued after 6 months so the last resort was to excise some of the nodules and use a splitskin graft.
The lack of response to treatment with dapsone and steroids could be explained by the advanced stage of the disease and significant fibrosis in the nodules [6] . In our experience we treated an HIV positive patient who had a biopsy proven Erythema Elevatum diutinum initially with Dapsone 50 mg od which lead to some improvement for 2 weeks but not change after. The dose was increased to 100 mg od after two months for next nine months. The lesions were gradually getting smaller with up to 50% improvement. Upon increasing the dose of Dapsone to 100/150 mg on alternate days it had a significant impact with 75% improvement (Figure 1) , despite the fact that in HIV there is advanced fibrosis and most cases might not respond to dapsone. EED with oral ulceration was treated with a combination of colchicine 500 micrograms 3 times daily, dapsone 50 mg on alternate days and mycofenolate and histopathology confirmed EED. The patient initially was treated with dapsone 100mg/day, and after the first 2 weeks the majority of the lesions resolved. But dapsone had to be stopped because the patient developed a hypersensitivity reaction to dapsone. So, after 4 weeks Colchicine 0.5 mg twice daily was administered instead of dapsone. The response to colchicine was slow with regression being noted in smaller lesions, while larger lesions were still in the process of regression [9] .
Histology Review
Histologically EED could present variably depending on the evolutionary stage of the disease. It may present with features of leukocytoclastic vasculitis at the early stage ( Figure 2) while at later stage it shows fibrosis and granulation tissue. 
Conclusion
EED is a rare skin condition, were treatment found to be challenging. A review of all treatment given showed Dapsone to be more effective than other treatment options. The higher dose of Dapsone seems to have an impact on response. A possible combination of treatment in the future might give even better response, again the earlier the patient is treated seems to respond better.
